ALBT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 04:00):

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China...

Stats
今日成交量	24 323.00
平均成交量	190 072
市值	3.42M
EPS	$0 ( 2024-05-20 )
下一个收益日期	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.190
ATR14	$0.00900 (2.92%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2021-05-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2022-05-01	Tauzin W J	Buy	8 000	Stock Option right to buy)
2022-11-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2022-01-01	Tauzin W J	Buy	4 000	Stock Option (right to buy)

INSIDER POWER
99.83
Last 100 transactions
Buy: 44 704 561 \| Sell: 8 187 803

Avalon GloboCare Corp. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Avalon GloboCare Corp. 财务报表

Annual	2023
营收:	$1.26M
毛利润:	$202 789 (16.15 %)
EPS:	$-1.590

FY	2023
营收:	$1.26M
毛利润:	$202 789 (16.15 %)
EPS:	$-1.590

FY	2022
营收:	$1.20M
毛利润:	$272 728 (22.69 %)
EPS:	$-1.360

FY	2021
营收:	$1.39M
毛利润:	$414 518 (29.80 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Avalon GloboCare Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Avalon GloboCare Corp.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.